Implementation for tuberculosis preventive therapy among latent tuberculosis infection in HIV-infected individuals using novel regimen of Isoniazid/Rifapentine daily (4 weeks) compared to Isoniazid/Rifapentine weekly (12 weeks)

Project no.: HIV-NAT 255/LTBI

Brief summary: This study is a multicenter, randomized, open-label, phase III clinical trial of INH/RPT (Isoniazid/Rifapentine) regimen administered daily for four weeks versus weekly dosing for 12 weeks in HIV-infected patients with latent TB infection (LTBI). This study will assess the efficacy of both regimens in preventing TB in HIV-infected participants. Also, this study will assess the safety and tolerability of the regimens, adherence to the treatments, and patterns of antibiotic resistance among those who had treatment failure. Some of the patients will be enrolled into the pharmacokinetic substudy that will look at the drug concentration of RPT when used with dolutegravir (DTG) / tenofovir alafenamide (TAF). This study aims to change the national guideline to improve the uptake of LTBI treatment